Zepbound Cost in South Dakota: Prices, Insurance, and Savings in 2026

What Zepbound Costs at South Dakota Pharmacies in 2026

The manufacturer list price for Zepbound is $1,059.87 per month across all dose strengths, and South Dakota retail pharmacies generally charge this amount for uninsured fills. Eli Lilly sets a single wholesale acquisition cost regardless of whether the prescription is filled in Sioux Falls, Rapid City, or a rural independent pharmacy.

This price applies to a four-week supply of single-dose pens. Patients begin at 2.5 mg weekly for four weeks, then escalate to 5 mg, with potential titration up to 15 mg based on clinical response and tolerability. Each escalation step uses the same list price. The FDA-approved prescribing information outlines six dose strengths (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg), all priced identically.

Cash-pay patients in South Dakota have limited negotiating power at chain pharmacies. GoodRx and similar discount aggregators may reduce the price by $50 to $150 in some cases, but tirzepatide remains one of the most expensive branded weight-management medications on the market. For context, semaglutide 2.4 mg (Wegovy) carries a comparable list price of roughly $1,349 per month, making Zepbound modestly less expensive at list [1].

Patients paying out of pocket should ask their pharmacy to run the prescription through manufacturer discount programs before processing the claim. Some patients report savings by switching between retail and specialty pharmacy channels, though availability varies by location.

South Dakota Medicaid and Zepbound Coverage

South Dakota Medicaid does not cover Zepbound for chronic weight management as of early 2026. This exclusion applies to both fee-for-service Medicaid and managed care plans administered through the state.

The state's formulary treats anti-obesity medications as a non-covered category, consistent with the federal Medicaid statute that historically excluded weight-loss drugs from mandatory coverage. While the Treat and Reduce Obesity Act has been reintroduced in Congress multiple times, it has not passed, and CMS has not issued guidance requiring state Medicaid programs to cover GLP-1 receptor agonists for obesity [2].

One exception exists. If a South Dakota Medicaid beneficiary has a concurrent type 2 diabetes diagnosis, tirzepatide may be accessible under its diabetes indication (marketed as Mounjaro). The drug is the same molecule at the same doses. Prescribers sometimes use this pathway when the patient's clinical profile supports both diagnoses, though prior authorization requirements apply and formulary placement varies by plan year.

South Dakota expanded Medicaid eligibility in 2023 after voters approved a ballot measure, bringing roughly 50,000 additional residents into coverage. None of these newly eligible beneficiaries have anti-obesity medication coverage through the program. Advocacy groups have pushed the state legislature to add obesity pharmacotherapy as a covered benefit, but no bill has advanced past committee as of May 2026.

Insurance Coverage for Zepbound in South Dakota

Commercial insurance coverage for Zepbound in South Dakota is inconsistent. Large employer-sponsored plans from carriers like Avera Health Plans, Sanford Health Plan, and national insurers (UnitedHealthcare, Blue Cross Blue Shield of South Dakota, Cigna) each set their own formulary rules.

Coverage typically requires prior authorization with documentation of a BMI of 30 or greater (or BMI of 27 or greater with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia). Many plans also require evidence of failed lifestyle modification, sometimes defined as participation in a structured diet and exercise program for three to six months [3].

"Coverage decisions for incretin-based obesity medications remain the single largest source of patient appeals in our prior authorization queue," said Dr. Robert Kushner, professor of medicine at Northwestern University Feinberg School of Medicine and past president of The Obesity Society.

Some plans impose step therapy, requiring patients to try and fail an older agent such as phentermine-topiramate (Qsymia) or naltrexone-bupropion (Contrave) before approving Zepbound. Others exclude anti-obesity medications entirely from their formulary, which is legal under current South Dakota insurance regulations.

Patients denied coverage should file a formal appeal. Include the prescriber's letter of medical necessity, BMI documentation, comorbidity records, and citations to clinical trial data. The SURMOUNT-1 trial, published in the New England Journal of Medicine, demonstrated that tirzepatide 15 mg produced 22.5% mean body weight reduction at 72 weeks compared to 3.1% with placebo (N=2,539), providing strong evidence of clinical benefit [1]. Plans that deny coverage despite strong clinical evidence may reverse their decision on appeal, particularly when the patient has documented comorbidities that tirzepatide could improve.

The Eli Lilly Savings Card and How It Works in South Dakota

Eli Lilly offers a manufacturer savings card for commercially insured patients that can reduce out-of-pocket Zepbound costs to as low as $25 per monthly fill. The card is accepted at all major retail pharmacies in South Dakota, including Walgreens, CVS, Lewis Drug, and independent pharmacies with compatible claims processing.

Eligibility requires active commercial insurance (employer-sponsored or individual marketplace plans). Patients with government insurance, including Medicaid, Medicare, TRICARE, and VA benefits, are excluded from the program. The savings card covers the difference between the patient's copay and $25, up to a maximum annual benefit that Lilly adjusts periodically [4].

To activate the card, patients register through the Zepbound website and present the card at the pharmacy along with their insurance information. The pharmacy runs a coordination of benefits, applying the insurance first and then the savings card to the remaining copay or coinsurance. If the pharmacy's system does not process the card automatically, the pharmacist can enter the BIN, PCN, and group numbers manually.

One common pitfall: the savings card does not apply if the patient's insurance plan excludes Zepbound from its formulary entirely. The card offsets copays on covered prescriptions, not denials. Patients whose plans issue a formal denial, rather than a high copay, need to pursue the appeal process or explore other options.

Lilly also launched its LillyDirect program, which allows patients to order Zepbound through a direct-to-patient pharmacy channel. Pricing through LillyDirect for cash-pay patients starts at $399 for lower doses and $549 for higher doses per month, representing a significant discount over the $1,059 list price for patients without insurance coverage.

Compounded Tirzepatide in South Dakota: Legality and Pricing

Compounded tirzepatide is available in South Dakota through licensed 503A compounding pharmacies. These pharmacies operate under state pharmacy board oversight and federal guidelines established by the Drug Quality and Security Act. The typical cost is approximately $249 per month, roughly 76% less than the branded product.

The legal basis for compounding tirzepatide shifted in 2024 and 2025 as the FDA updated its drug shortage list. When tirzepatide appeared on the shortage list, 503A and 503B pharmacies could compound copies of the drug without violating federal law. After the FDA resolved the shortage designation, legal ambiguity emerged. As of May 2026, the FDA's enforcement posture toward compounded tirzepatide remains in flux, with ongoing litigation between compounding pharmacy trade groups and the agency [5].

In South Dakota, 503A pharmacies require a valid patient-specific prescription from a licensed prescriber to compound tirzepatide. The South Dakota Board of Pharmacy regulates these pharmacies and requires adherence to USP 797 sterile compounding standards. Patients should verify that their compounding pharmacy holds a current state license and performs third-party potency and sterility testing on each batch.

"Patients considering compounded peptides should confirm that the pharmacy tests every batch for potency, sterility, and endotoxins," said Dr. Caroline Apovian, professor of medicine at Harvard Medical School and co-director of the Center for Weight Management and Metabolic Surgery at Brigham and Women's Hospital.

Compounded tirzepatide comes as a multi-dose vial requiring the patient to draw and inject the correct volume using an insulin syringe. This differs from Zepbound's pre-filled single-dose pen, which requires no dose measurement. Patients unfamiliar with vial-and-syringe technique should receive hands-on training from their prescriber or pharmacist to reduce dosing errors and injection site complications.

Quality varies among compounders. Not all 503A pharmacies produce equivalent products. Patients should ask for a certificate of analysis for their specific batch, confirming that the tirzepatide concentration matches the label claim within acceptable variance (typically plus or minus 10%).

Getting Zepbound via Telehealth in South Dakota

Telehealth prescribing of Zepbound is legal in South Dakota and has become a common access pathway, particularly for patients in rural areas far from obesity medicine specialists. South Dakota's telehealth parity law requires insurers to cover telehealth visits at the same rate as in-person encounters, though the medication itself is subject to the plan's formulary rules [6].

Several national telehealth platforms prescribe Zepbound to South Dakota residents. These services typically charge a monthly membership fee ($50 to $150) and connect patients with physicians or nurse practitioners licensed in South Dakota. The consultation includes a medical history review, BMI calculation, lab work (often ordered through local Quest or Labcorp draw sites), and prescription issuance if clinically appropriate.

The Ryan Haight Act requires that a prescriber-patient relationship exist before prescribing controlled substances via telehealth, but tirzepatide is not a controlled substance, so this restriction does not apply. A telehealth prescriber can evaluate and prescribe Zepbound during a single video visit without a prior in-person examination.

Patients using telehealth should confirm that the prescriber will manage dose titration, monitor for adverse effects (including pancreatitis risk, which the FDA label warns about), and order periodic labs including lipid panels and hemoglobin A1c when indicated. Weight-management medications require ongoing clinical oversight. A prescription without follow-up is substandard care.

How Zepbound Compares to Other Weight-Loss Options in South Dakota

Tirzepatide's clinical profile sets it apart from other FDA-approved anti-obesity medications available in South Dakota pharmacies. In SURMOUNT-1, participants on the 15 mg dose lost a mean of 22.5% of body weight at 72 weeks. The 10 mg dose produced 21.4% weight loss, and the 5 mg dose produced 16.0%, all significantly greater than the 3.1% observed with placebo (P<0.001 for all comparisons) [1].

By comparison, semaglutide 2.4 mg (Wegovy) produced 14.9% mean weight loss at 68 weeks in the STEP-1 trial (N=1,961) [7]. Older agents produce more modest results: phentermine-topiramate extended-release yields approximately 9.8% weight loss, and naltrexone-bupropion produces roughly 5-6% at one year [8].

Tirzepatide's dual mechanism, activating both the GIP and GLP-1 receptors, likely accounts for its greater efficacy. GIP receptor activation enhances insulin sensitivity and may independently affect adipose tissue metabolism, an effect not shared by GLP-1-only agonists [9].

| Medication | Mean Weight Loss | Monthly Cost (Cash) | |---|---|---| | Zepbound (tirzepatide) 15 mg | 22.5% at 72 wk | $1,059 | | Wegovy (semaglutide) 2.4 mg | 14.9% at 68 wk | ~$1,349 | | Qsymia (phentermine-topiramate) | ~9.8% at 56 wk | ~$200 | | Contrave (naltrexone-bupropion) | ~5.6% at 56 wk | ~$100 | | Compounded tirzepatide (503A) | Expected similar to branded | ~$249 |

South Dakota patients weighing cost against efficacy should discuss these options with their prescriber. For patients with BMI over 35 and type 2 diabetes, tirzepatide offers the added benefit of substantial glycemic improvement, with A1c reductions of 2.1 percentage points observed in the SURPASS trials for the diabetes indication [10].

Strategies to Reduce Zepbound Costs in South Dakota

South Dakota residents paying full price have several concrete options to lower their monthly spend on tirzepatide.

LillyDirect: Eli Lilly's direct pharmacy channel offers single-dose vials (not pens) at $399 to $549 per month for cash-pay patients. This requires a prescription but no insurance.

Compounded tirzepatide: At approximately $249 per month from a licensed 503A pharmacy, this remains the lowest-cost option. Verify pharmacy credentials with the South Dakota Board of Pharmacy.

Employer advocacy: Some South Dakota employers, particularly larger organizations like Sanford Health, Avera, and state government, are adding anti-obesity medication coverage in response to employee demand. Patients can contact their HR department to request formulary review.

Clinical trials: ClinicalTrials.gov lists active tirzepatide studies that may provide the drug at no cost. Availability in South Dakota is limited, but multi-site trials sometimes include satellite locations in Sioux Falls or remote monitoring options.

Patient assistance programs: Lilly's patient assistance program (Lilly Cares) provides free medications to qualifying uninsured patients with household incomes below 400% of the federal poverty level. Applications require prescriber involvement and income documentation.

Patients prescribed tirzepatide for type 2 diabetes (as Mounjaro rather than Zepbound) may find broader insurance coverage, as diabetes indications receive more consistent formulary placement than obesity indications across most South Dakota health plans.